Prelude Therapeutics Inc.

09/17/2021 | Press release | Distributed by Public on 09/17/2021 06:32

Management Change/Compensation (Form 8-K)

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 16, 2021, Prelude Therapeutics Incorporated. (the 'Company') received notice from Christopher Pierce of his intention to resign as Executive Vice President and Chief of Business Operations of the Company effective on September 30, 2021, in order to pursue another employment opportunity.